1. Scrip
  2. >>New Products

BeyondSpring's Next Move Uncertain After Plinabulin CRL

Limited Impact On China Partner Hengrui?

 
• By Brian Yang

Chinese firm BeyondSpring dealt a setback after the US FDA refuses to approve plinabulin for chemotherapy-induced neutropenia.

Business uncertainty and risk showing a winding road high above the clouds showing the concept of danger and challenges faced in business and the corporate world of finance and financial services.
BEYONDSPRING'S PLINABULIN GETS US CRL, NEXT MOVE UNCERTAIN • Source: Alamy

On 1 December, Chinese biotech BeyondSpring Inc. said it had received a Complete Response Letter (CRL) from the US Food and Drug Administration, under which the agency refused to approve its drug plinabulin for chemotherapy-induced neutropenia due to results from the single Phase III registrational trial being “not sufficiently robust to demonstrate benefits" and meaning a second well-controlled trial will be required.

The small molecule treatment is designed for use in combination with granulocyte colony-stimulating factor (G-CSF) for cancer patients with

More from New Products

More from Scrip

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.